ENA Sectors 2025-08-27 17:07:54 <p><span style="font-size:14px"><strong>New Delhi, Aug 27 (KNN) </strong>Indias Contract Research, Development, and Manufacturing Organisation (CRDMO) sector, currently valued at around USD 3 billion, is set to grow rapidly in the coming years.</span></p> <p><span style="font-size:14px">According to a report by Jefferies, the industry is expected to expand at an 18% compound annual growth rate (CAGR) from FY25 to FY30, outpacing the 14% growth seen over the past five years.</span></p> <p><span style="font-size:14px">This growth is being driven by several key factors. Global pharmaceutical companies are increasingly adopting the China+1 strategy, diversifying their supply chains to reduce dependence on China.</span></p> <p><span style="font-size:14px">Additionally, rising demand for treatments targeting obesity and type 2 diabetes, along with advancements in antibody-drug conjugates (ADCs), is further boosting the sector. Indian CRDMOs are well-positioned to benefit from these trends due to their strong capabilities and established track record.</span></p> <p><span style="font-size:14px">Over the years, Indias CRDMO industry has transformed from a secondary player into a strategic partner for global pharmaceutical innovators. This evolution has attracted significant investor interest, with the sectors market capitalisation now estimated at $40 50 billion.</span></p> <p><span style="font-size:14px">Companies like Sai Life Sciences, Cohance Lifesciences, Divis Laboratories, and Piramal Pharma are emerging as major global partners, benefiting from robust pipeline visibility and increasing demand for advanced therapies.</span></p> <p><span style="font-size:14px">However, challenges such as the need for regulatory reforms and infrastructure improvements remain critical to sustaining competitiveness.</span></p> <p><span style="font-size:14px">Analysts suggest that continued investment in innovation, technology, and manufacturing capacity will be crucial for India to solidify its position as a global leader in pharmaceutical manufacturing.</span></p> <p><span style="font-size:14px">With strategic diversification and evolving treatment landscapes, Indias CRDMO sector is poised for a strong growth trajectory, offering significant opportunities for investors and global pharma partners alike.</span></p> <p><em><strong><span style="font-size:14px">(KNN Bureau)</span></strong></em></p> 43296 https://knnindia.co.in/news/newsdetails/sectors/indias-contract-drug-manufacturing-set-to-grow-at-18-jefferies 2025-08-27 17:07:54 knnindia.co.in